In vivo instability of 177Lu-DOTATATE during peptide receptor radionuclide therapy.

MLA

Lubberink, Mark, et al. “In Vivo Instability of 177Lu-DOTATATE during Peptide Receptor Radionuclide Therapy.” Journal of Nuclear Medicine, vol. 61, no. 7, July 2020, pp. 1–16. EBSCOhost, https://doi.org/10.2967/jnumed.119.237818.

APA

Lubberink, M., Wilking, H., Öst, A., Ilan, E., Sandström, M., Andersson, C., Fröss-Baron, K., Velikyan, I., & Sundin, A. (2020). In vivo instability of 177Lu-DOTATATE during peptide receptor radionuclide therapy. Journal of Nuclear Medicine, 61(7), 1–16. https://doi.org/10.2967/jnumed.119.237818

Chicago

Lubberink, Mark, Helena Wilking, Amalia Öst, Ezgi Ilan, Mattias Sandström, Camilla Andersson, Katarzyna Fröss-Baron, Irina Velikyan, and Anders Sundin. 2020. “In Vivo Instability of 177Lu-DOTATATE during Peptide Receptor Radionuclide Therapy.” Journal of Nuclear Medicine 61 (7): 1–16. doi:10.2967/jnumed.119.237818.